Tumor-infiltrating lymphocytes (TILs) from the patients with lung adenocarcinoma (LUAD), for instance, express higher levels of CD96 and lower levels of CD226 than that in the peripheral circulating blood, which suggests an imbalance between CD96 and CD226 resulting in the decreased tumor immune response in LUAD. The gene discussed is CD96; the disease is lung adenocarcinoma.